摘要
目的:观察奥曲肽(OTC)联合吉西他滨和奥沙利铂(GEMOX)方案治疗晚期胰腺癌,评估其有效性、安全性、疾病相关症状改善状况(DRSI)。方法:57例晚期胰腺癌患者随机分为2组,治疗组29例,采用OCT联合GEMOX方案化疗,对照组28例,采用GEMOX方案化疗,至少用药3周期,以近期疗效、DRSI、血清癌胚抗原(CEA),血清CA199及不良反应为观察指标。结果:两组间客观有效率、疾病控制率差异无统计学意义(P>0.05)。OCT联合GEMOX方案组DRSI为58.62%,GEMOX方案组DRSI为28.57%,两组间差异有统计学意义(P<0.05)。两组间治疗前后血清癌胚抗原(CEA),血清CA199无统计学差异(P>0.05)。OCT联合GEMOX方案组胃肠道反应明显低于GEMOX方案组,组间存在明显差异(P<0.05)。两组间其他相关毒性反应无明显差异(P>0.05)。无严重不良反应发生。结论:OCT联合GEMOX方案治疗晚期胰腺癌可获得较高的DRSI,并且化疗相关的胃肠道反应明显减轻,其不良反应可耐受,没有引起严重并发症。患者化疗耐受性良好,生活质量改善,可能有助于胰腺癌患者从化疗中获益。
Objective ：To investigate the effectiveness and safety and disease -related symptoms improved （DR- SI） of octreotide （OTC） combined with gemcitabine and oxaliplatin （GEMOX） in treatment of advanced pancreatic cancer. Methods：All 57 patients with advanced pancreatic cancer were randomly divided into two groups, 29 cases were treated by OCT combined with GEMOX,in the control group 28 cases were treated by GEMOX, at least 3 cycles. The short- term efficacy, DRSI and serum carcinoembryonic antigen （CEA）, serum CA199 and adverse reactions were observed. Results：The disease control rate and the objective response rate between the two groups were not sig- nificantly different （P 〉 0.05 ）. DRSI in the group of OCT - GEMOX was 58.62%, DRSI in the group of GEMOX was 28.57% ,the difference between the two groups was significant statistically （ P 〈 0.05 ）. The level of CEA and CA199 was no difference in two groups （P 〉 0.05 ） Gastrointestinal reactions of OCT - GEMOX was lower than GE- MOX, the significant differences existed between the two groups （P 〈 0.05 ）. Other toxicity was not significantly dif- ferent between two groups （ P 〉 0.05 ）. There were no serious adverse events in the two groups. Conclusion： OCT - GEMOX in treatment of advanced pancreatic cancer obtained higher DRSI, the chemotherapy - related gastrointestinal reactions was reduced. The serious complications were not observed. OCT combined with GEMOX regimen is well - tolerated in patients with advanced pancreatic cancer. The improvement in the quality of life of patients may help pa- tients benefiting from chemotherapy.
出处
《现代肿瘤医学》
CAS
2015年第4期527-530,共4页
Journal of Modern Oncology
关键词
胰腺癌
化学疗法
奥曲肽
pancreatic cancer
chemotherapy
octreotide
